Regulus, Alnylam, and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series

- Tuschl III Patent Exclusively Licensed from Max Planck -
CARLSBAD, Calif. & CAMBRIDGE, Mass.--(Business Wire)--
Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent
Office (JPO) has notified the Max Planck Society of its intent to grant a patent
from the Tuschl III patent series (JP Application Number 2003-532675). This
patent series pertains to the discovery of over 120 novel mammalian microRNAs,
including miR-122, which is a leading pre-clinical program at Regulus. The grant
of this first Tuschl III patent in Japan extends the scope of this patent
estate, which has already yielded patents in the U.S. (U.S. Patent No.
7,232,806) and in Australia (Australian Patent No. 2002 347 035).

The Tuschl III patent series stems from groundbreaking research (Lagos-Quintana
et al., (2001) Science 294, 853-858) performed by Alnylam founder and Regulus
scientific advisory board member Dr. Thomas Tuschl, Associate Professor of RNA
Molecular Biology at The Rockefeller University, while at the Max Planck
Society. The Tuschl III patent series is exclusively held by Regulus for
microRNA therapeutics through license agreements amongst Max Planck, Alnylam,
and Isis.

"Regulus is advancing a whole new frontier of pharmaceutical research through
the discovery of microRNA therapeutics, which have the potential to affect broad
disease pathways as opposed to single gene targets," said Kleanthis G.
Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus
Therapeutics. "Through our partnerships with Alnylam, Isis, and our
relationships with leading academic institutions such as the Max Planck, we have
built a dominant intellectual property estate for the development of microRNA
therapeutics. This is first in the Tuschl III series to grant in Japan, and we
expect more to come from this important and early patent series."

"We are pleased with the continued recognition of the pioneering contributions
of Professor Tuschl`s work performed at the Max Planck," said Dr. Joern
Erselius, Managing Director, Max Planck-Innovation GmbH. "The Tuschl III patent
series describes an important set of discoveries for the advancement of microRNA
therapeutics. With Regulus, we have an ideal partner for the development of this
seminal research into a promising new approach for medicine."

The newly granted claims of the Tuschl III patent cover miR-122, a
liver-specific microRNA that has subsequently been shown to facilitate
replication of hepatitis C virus (HCV) infection. The claims cover
single-stranded and double-stranded antisense compounds complementary to
mir-122, as well as precursors and analogs of mir-122.

Regulus is advancing microRNA therapeutics targeting miR-122, among others.
Pre-clinical studies suggest that miR-122 is essential for the replication of
HCV (Jopling et al. (2005) Science 309, 1577-81) and that creating an inhibitor
to miR-122 may define a novel therapeutic strategy for the treatment of HCV
infection.

About microRNAs

microRNAs are small, non-coding RNAs that regulate a large number of human
genes; there are more than 700 microRNAs in the human genome that play a role in
controlling expression of over one-third of all human genes. Abnormal expression
and genetic mutation of microRNAs have been linked to numerous diseases
including cancer, cardiovascular disease, metabolic disease, autoimmunity, and
viral infection, among others. In 2005, Alnylam scientists and collaborators at
The Rockefeller University were the first to describe antagomirs, which are part
of a larger class of microRNA inhibitors known as anti-miRs (Krutzfeldt et al.,
(2005) Nature 438, 685-689). Anti-miRs were created to selectively inhibit
microRNAs expressed in a broad range of tissues and to have pharmacological
properties required for microRNA-based therapeutics. This research has created
new drug discovery strategies focused on antagonizing microRNAs.

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. is a biopharmaceutical company aiming to discover,
develop, and commercialize microRNA-based therapeutics. Regulus aspires to
translate one of the most important new discoveries in biology into a novel
approach for innovative medicines and to build the leading microRNA company.
Regulus was established by Alnylam Pharmaceuticals (Nasdaq: ALNY) and Isis
Pharmaceuticals (Nasdaq: ISIS) in September of 2007, and benefits substantially
from their RNA therapeutic drug discovery expertise, unique and established
oligonucleotide-based technologies, and a broad and dominant intellectual
property estate specific to microRNA-based therapeutics. Regulus` patent estate
includes over 600 patents and more than 300 pending patent applications
pertaining primarily to chemical modifications of oligonucleotides targeting
microRNA for therapeutic applications. In addition, through its numerous
collaborations with academic researchers, Regulus continues to expand its
knowledge on the biological role of therapeutically relevant microRNAs. In April
2008, Regulus formed a major alliance with GlaxoSmithKline to explore microRNA
therapeutics for immuno-inflammatory diseases. Regulus is headquartered in
Carlsbad, California. For more information, visit www.regulusrx.com.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is applying its therapeutic expertise in
RNAi to address significant medical needs, many of which cannot effectively be
addressed with small molecules or antibodies, the current major classes of
drugs. Alnylam is leading the translation of RNAi as a new class of innovative
medicines with peer-reviewed research efforts published in the world`s top
scientific journals including Nature, Nature Medicine, and Cell. The company is
leveraging these capabilities to build a broad pipeline of RNAi therapeutics;
its most advanced program is in Phase II human clinical trials for the treatment
of respiratory syncytial virus (RSV) infection and is partnered with Cubist and
Kyowa Hakko Kirin. In addition, the company is developing RNAi therapeutics for
the treatment of a wide range of disease areas, including liver cancers, TTR
amyloidosis, hypercholesterolemia, and Huntington`s disease. The company`s
leadership position in fundamental patents, technology, and know-how relating to
RNAi has enabled it to form major alliances with leading companies including
Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist.
To reflect its outlook for key scientific, clinical, and business initiatives,
Alnylam established "RNAi 2010" in January 2008 which includes the company`s
plan to significantly expand the scope of delivery solutions for RNAi
therapeutics, have four or more programs in clinical development, and to form
four or more new major business collaborations, all by the end of 2010. Alnylam
and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the
discovery, development, and commercialization of microRNA-based therapeutics.
Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For
more information, please visit www.alnylam.com.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for
its product pipeline and for its partners. The Company has successfully
commercialized the world`s first antisense drug and has 19 drugs in development.
Isis` drug development programs are focused on treating cardiovascular,
metabolic and severe neurodegenerative diseases and cancer. Isis` partners are
developing antisense drugs invented by Isis to treat a wide variety of diseases.
Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc.,
a company focused on the discovery, development and commercialization of
microRNA therapeutics. Isis also has made significant innovations beyond human
therapeutics resulting in products that other companies, including Abbott, are
commercializing. As an innovator in RNA-based drug discovery and development,
Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.
Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future
therapeutic and commercial potential of Regulus`, Alnylam`s, and Isis` business
plans, technologies and intellectual property related to microRNA therapeutics
being discovered and developed by Regulus. Any statement describing Regulus`,
Alnylam`s, and Isis` goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be considered an
at-risk statement, including those statements that are described as such
parties` goals. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such products. Such parties`
forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause their results to differ materially
from those expressed or implied by such forward-looking statements. Although
these forward-looking statements reflect the good faith judgment of the
management of each such party, these statements are based only on facts and
factors currently known by Regulus`, Alnylam`s, and Isis` as the case may be. As
a result, you are cautioned not to rely on these forward-looking statements.
These and other risks concerning Regulus`, Alnylam`s, and Isis` programs are
described in additional detail in Alnylam`s and Isis` annual reports on Form
10-K for the year ended December 31, 2008, and their most recent quarterly
reports on Form 10-Q which are on file with the SEC. Copies of these and other
documents are available from Alnylam or Isis.

Regulus Therapeutics
Garry E. Menzel, Ph.D., 760-268-6811
or
Media
Russo Partners
Heidi Chokeir, Ph.D., 619-528-2217
or
Alnylam Pharmaceuticals
Investors
Cynthia Clayton, 617-551-8207
or
Media
Yates Public Relations
Kathryn Morris, 845-635-9828
or
Isis Pharmaceuticals
Investors
Kristina Lemonidis, 760-603-2490
or
Media
Amy Blackley, Ph.D., 760-603-2772

Copyright Business Wire 2009